Prospective studies are needed to elucidate the clinical impact of predominant Api m 10 sensitization - Figure 2

Venom immunotherapy (VIT) is the treatment of choice for patients with Hymenoptera venom allergy and provides long-term protection from further generalized reactions in as many as 95-99% of patients treated with vespid venom, and 75-85% of patients treated with bee venom. Beside well known risk factors like elevated tryptase levels it is believed that predominant Api m 10 sensitization is as well a risk factor for treatment failure in bee VIT. However, this assumption is based on a single publication This small pilot study shows that other predominant sensitizations, such as Api m 2 and 5, may also play an important role in bee venom allergic patients with therapy failure and not only a predominant sensitization to Api m 10 as speculated since years. The provided dataset contains all relevant data for Figure 2 of the publication.